Miliary Tuberculosis
What is Miliary Tuberculosis?
Miliary tuberculosis (or disseminated tuberculosis) is a severe form of tuberculosis characterized by hematogenous dissemination of Mycobacterium tuberculosis throughout the body. Micro tuberculous granulomas (1-2 mm) form in numerous organs: lungs, meninges (tuberculous meningitis), liver, spleen, kidneys, bone marrow, lymph nodes, serous membranes (pericardium, pleura). It is an absolute medical emergency with a life-threatening prognosis (mortality 20-50% without rapid treatment).
Miliary TB gets its name from radiological images: micronodules (1-3 mm) disseminated throughout both lungs, resembling "millet seeds" (milia).
Risk Factors
- Severe immunosuppression: HIV/AIDS (CD4 < 200), prolonged corticosteroid therapy, immunosuppressants (transplant recipients, autoimmune diseases), chemotherapy, hematologic malignancies (leukemia, lymphoma).
- Extremes of age: infants (< 1 year), elderly (> 80 years).
- Severe malnutrition (BMI < 16).
- Diabetes, chronic kidney disease, chronic alcoholism.
- Originating from a high TB endemic country (Sub-Saharan Africa, Southeast Asia, Eastern Europe, Maghreb including Tunisia).
What are the signs of Miliary Tuberculosis? (Symptoms)
The clinical presentation is often asthenic and febrile, sometimes misleading (flu-like syndrome).
General Signs (constant, present in > 90% of cases)
- Prolonged fever (> 38-39°C): often remittent (oscillating), sometimes continuous (daily).
- Significant weight loss (10-20% of body weight within weeks).
- Severe asthenia (intense fatigue), anorexia.
- Profuse night sweats (tuberculous impregnation).
- Decline in general condition (sign of severity).
Respiratory Signs (common)
- Progressive dyspnea (shortness of breath on exertion then at rest).
- Dry or non-productive cough (little sputum).
- Chest pain (associated tuberculous pleurisy in 10-20% of cases).
- Crackling rales on auscultation (often subtle).
- Acute respiratory distress syndrome (ARDS) in the most severe forms (life-threatening emergency).
Neurological Signs (associated tuberculous meningitis, 20-40% of cases)
- Intense headaches, neck stiffness (meningism).
- Confusion, drowsiness, coma (Glasgow ≤ 8).
- Seizures, focal neurological deficit.
- Signs of intracranial hypertension (ICH).
Other Organ Signs (dissemination)
- Hepatomegaly, splenomegaly (palpable liver and spleen).
- Liver failure (jaundice, cytolysis, hepatocellular failure).
- Kidney failure (elevated creatinine, proteinuria, hematuria).
- Pancreatitis (abdominal pain, elevated lipase).
- Pericarditis (chest pain, pericardial effusion, risk of tamponade).
- Multiple lymphadenopathy (cervical, axillary, abdominal).
- Uveitis (visual disturbances), cutaneous tuberculosis (rare).
How is Miliary Tuberculosis Diagnosed in Tunisia?
Diagnosis is urgent in cases of prolonged fever with declining general condition. Confirmation relies on imaging, microbiology, and sometimes biopsy.
Chest Imaging (key criterion)
- Chest X-ray:
- Typical appearance (classic): diffuse bilateral micronodules (1-3 mm), uniform in size, with ill-defined borders, distributed throughout all lung fields ("balloon release appearance").
- Atypical forms: blurred miliary (poorly defined opacities), miliary with alveolar syndrome (ARDS), localized miliary.
- Normal X-ray possible in 10-20% of cases initially (repeat at D7-10).
- Chest CT scan (high resolution, reference exam):
- Perfect visualization of centrilobular micronodules (1-3 mm), sometimes confluent.
- Search for cavities (often absent in pure miliary), mediastinal lymphadenopathy.
- Sensitivity > 95% (even if X-ray normal).
Brain and Abdominal Imaging
- Brain MRI (with gadolinium injection): detection of tuberculous meningitis (basal meningeal enhancement, cerebral tuberculomas, hydrocephalus).
- Abdominal CT scan: hepatomegaly, splenomegaly, deep lymphadenopathy, hypodense liver or spleen lesions (tuberculomas).
Microbiology (bacteriological confirmation)
- Acid-fast bacilli (AFB) smear microscopy:
- Sputum (3 samples, including one morning): low sensitivity (30-50%).
- Bronchoalveolar lavage (BAL) fluid by bronchoscopy (sensitivity 60-80%).
- Gastric fluid (children, non-expectorating patients).
- Cerebrospinal fluid (CSF) if tuberculous meningitis suspected.
- Other biopsies (liver, bone marrow, lymph nodes).
- GeneXpert MTB/RIF PCR (reference exam, 2h turnaround): on sputum, BAL, CSF, biopsies. Detects Mycobacterium tuberculosis and rifampicin resistance. High sensitivity (70-90%).
- Mycobacterial culture (Lowenstein-Jensen, MGIT): gold standard (sensitivity 80-100%), 3-6 week delay, allows full antibiogram.
- Resistance test (Hain test, line probe assay): detection of resistance to INH, RMP, FQ, injectables (2-3 days).
Biopsy (histological diagnosis)
- Bone marrow biopsy: epithelioid giant cell granulomas (80-90% sensitivity in miliary).
- Liver biopsy: hepatic granulomas (90% sensitivity, but hemorrhagic risk).
- Lymph node biopsy (peripheral lymphadenopathy): granulomas, culture, PCR.
- Pleural biopsy (tuberculous pleurisy): granulomas (50-70%).
Laboratory Tests
- Tuberculin skin test (PPD): often negative (anergy, immunosuppression).
- IGRA (Quantiferon-TB Gold, T-SPOT.TB): often positive (but does not distinguish latent infection/active disease).
- Inflammatory syndrome (elevated CRP, normal or moderate procalcitonin, hyperleukocytosis, anemia).
- Hyponatremia (SIADH): common in cerebral/meningeal involvement.
- Liver function tests (cytolysis, cholestasis, liver failure).
- Kidney function tests (creatinine, proteinuria, hematuria).
- HIV serology (mandatory, as co-infection is common).
How is Miliary Tuberculosis Managed in Tunisia?
Miliary tuberculosis is an emergency. Treatment must be initiated as soon as clinical and radiological suspicion arises, without waiting for microbiological results.
Quadruple Anti-tuberculosis Therapy (initial phase 2 months)
Standard protocol (WHO, Tunisian national recommendations)
- Isoniazid (INH): 5 mg/kg/day (max 300 mg/day) (oral or IV if tube/coma).
- Rifampicin (RMP): 10 mg/kg/day (max 600 mg/day) (oral or IV).
- Pyrazinamide (PZA): 20-30 mg/kg/day (max 2 g/day) (oral).
- Ethambutol (EMB): 15-20 mg/kg/day (max 1.2 g/day) (oral, < 5 years often replaced by streptomycin or not given if meningitis suspected).
If associated tuberculous meningitis: replace ethambutol with streptomycin (15 mg/kg/day IM) or ofloxacin (avoids optic neuritis).
Corticosteroid therapy (dexamethasone or prednisone): systematic in cases of tuberculous meningitis (grade A) (reduces mortality and sequelae). Prednisone 1 mg/kg/day for 4-6 weeks then taper.
Parenteral route (IV): if comatose patient, swallowing disorders, severe ARDS, shock. Isoniazid, rifampicin (IV available in Tunisia), amikacin/streptomycin (IM).
Continuation Phase (4-7 months)
- Isoniazid + Rifampicin (RH) at same doses (dual therapy).
- Total duration: 6 months (uncomplicated forms) to 9-12 months (tuberculous meningitis, severe miliary, severe immunosuppression, HIV, bone).
- Oral administration (or IV if resolved).
Intensive Care Management (severe forms)
Patients with severe miliary tuberculosis are hospitalized in multidisciplinary or respiratory intensive care units.
Indications for ICU Admission:
ICU admission is essential for patients with severe miliary tuberculosis complicated by Acute Respiratory Distress Syndrome (ARDS) with a PaO2/FiO2 ratio below 200 requiring mechanical ventilation, coma with a Glasgow score ≤ 8 or rapid neurological deterioration, septic shock with hypotension requiring vasopressors, acute kidney failure with anuria or severe hyperkalemia requiring hemofiltration, acute liver failure with hepatic encephalopathy, or multiple organ dysfunction syndrome (MODS) with short-term life-threatening prognosis.
ICU Management:
ICU management of severe miliary tuberculosis is based on several complementary therapeutic axes. In cases of ARDS, invasive mechanical ventilation is initiated with lung-protective settings including low tidal volume (4-6 mL/kg), high PEEP (10-15 cmH2O), and prone positioning when PaO2/FiO2 is below 150. In septic shock, vasopressors (norepinephrine) are administered to maintain mean arterial pressure ≥ 65 mmHg. In anuric acute kidney injury, severe acidosis, or life-threatening hyperkalemia, continuous hemofiltration (CVVHDF) is started. Intravenous anti-tuberculosis drugs (INH, RMP, amikacin if resistance) are given in the initial phase, with early oral switch between day 7 and 14. Corticosteroids (dexamethasone 0.15-0.3 mg/kg/day) are systematic for associated tuberculous meningitis or severe ARDS. Rigorous neurological monitoring is ensured with hourly Glasgow Coma Scale and monitoring for signs of intracranial hypertension (bradycardia, hypertension, miosis, respiratory changes). Intracranial pressure monitoring via intraparenchymal sensor is indicated for severe tuberculous meningitis with risk of brain herniation.
Treatment of Complications and Supportive Care
Management of specific complications of miliary tuberculosis requires a targeted approach. For tuberculous meningitis, dexamethasone is administered at 0.3 mg/kg/day with gradual tapering over 4-6 weeks, combined if necessary with ventricular shunting to treat hydrocephalus and intracranial pressure monitoring. For tuberculous pericarditis complicated by tamponade, emergency ultrasound-guided pericardiocentesis is performed, supplemented by corticosteroids at 1 mg/kg/day. When liver failure occurs, due to drug-induced hepatitis from isoniazid, rifampicin, or pyrazinamide, close monitoring of transaminases (AST and ALT) is instituted; in severe hepatitis with transaminases > 3-5 times normal accompanied by clinical signs, pyrazinamide and sometimes rifampicin are reduced or temporarily stopped, replaced by ofloxacin and amikacin or streptomycin dual therapy. The appearance of visual disturbances under ethambutol, indicating potentially irreversible optic neuritis, requires immediate drug discontinuation and switch to ofloxacin 400 mg/day. Furthermore, severe malnutrition common in these patients requires enteral nutrition via nasogastric tube with caloric goal of 25-30 kcal/kg/day. Finally, systematic prophylaxis for pressure ulcers, deep vein thrombosis, and gastric ulcers with proton pump inhibitors is instituted for bedridden patients and/or those on prolonged corticosteroid therapy.
Clinical, Laboratory, and Radiological Monitoring
Clinical monitoring of a patient treated for miliary tuberculosis involves regular assessment of temperature, weight, and respiratory, neurological, hepatic, and cutaneous symptoms to detect any worsening or side effects. Monthly laboratory tests are systematically performed, including complete blood count, transaminases (AST and ALT), bilirubin, creatinine, and C-reactive protein (CRP), whose normalization is expected within 4-6 weeks. Control chest X-ray is performed at 2 months and 6 months to document the progressive resolution of pulmonary micronodules. Finally, specialized examinations are necessary depending on the anti-tuberculosis drugs used: audiogram to monitor ototoxicity of streptomycin or amikacin, and regular fundoscopic exam to screen for possible ethambutol-induced optic neuritis.
Treatment of Associated HIV Infection
In patients co-infected with HIV and miliary tuberculosis, it is imperative to start anti-tuberculosis treatment (quadruple therapy) two to eight weeks before introducing antiretrovirals (ARVs) to prevent Immune Reconstitution Inflammatory Syndrome (IRIS), which manifests as paradoxical worsening of tuberculous symptoms when the immune system recovers. The preferred antiretrovirals are efavirenz combined with tenofovir and emtricitabine (TDF/FTC), avoiding protease inhibitors like ritonavir which have significant drug interactions with rifampicin. Enhanced clinical and laboratory monitoring is essential for early detection of any signs of IRIS and appropriate management adjustment.
What are the Risks and Complications of Miliary Tuberculosis?
Miliary tuberculosis exposes patients to numerous serious complications, dominated by Acute Respiratory Distress Syndrome (ARDS) which occurs in 20-40% of cases and is the leading cause of death, and tuberculous meningitis, present in 20-40% of miliary cases, with mortality reaching 20-50% and leaving severe neurological sequelae (hemiplegia, epilepsy, mental retardation) in 30-60% of survivors. Other dreaded complications include acute liver failure (tuberculous hepatitis), acute kidney failure (tuberculous tubulointerstitial nephritis), constrictive pericarditis as a late sequela, disseminated intravascular coagulation (DIC), septic shock with multiple organ failure, and Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-coinfected patients, manifesting as paradoxical worsening of symptoms after starting antiretrovirals. Furthermore, severe drug side effects are not uncommon: isoniazid can cause hepatitis in 2-10% of cases and peripheral neuropathy (prevented by pyridoxine 25-50 mg/day); rifampicin causes benign red discoloration of urine and sweat, hepatitis in 1-2% of cases, and sometimes purpura or flu-like syndrome; pyrazinamide may cause hepatitis and hyperuricemia leading to arthralgias or even gout attacks; ethambutol can induce dose-dependent optic neuritis (eye pain, decreased visual acuity, blue-yellow dyschromatopsia) reversible upon drug discontinuation; finally, streptomycin and amikacin are nephrotoxic and ototoxic, potentially causing irreversible deafness and vertigo.
Prognosis of Miliary Tuberculosis
Mortality from miliary tuberculosis varies considerably depending on the context, ranging from 10-30% in developed countries where management is rapid and optimal, to 30-50% in developing countries, particularly in HIV-infected patients or when diagnosis is delayed. Several factors are associated with poor prognosis, including age over 65 years, severe immunosuppression with CD4 lymphocyte count below 50 in HIV-positive patients, presence of Acute Respiratory Distress Syndrome (ARDS) with PaO2/FiO2 ratio below 150, tuberculous meningitis complicated by coma with Glasgow score ≤ 8, severe liver involvement, multiple organ failure, or treatment delay exceeding 2-4 weeks after symptom onset. Sequelae observed in survivors can be severe and include chronic respiratory failure due to pulmonary fibrosis or atelectasis, neurological sequelae such as epilepsy, hemiplegia, or cognitive disorders, as well as chronic kidney failure or constrictive pericarditis.
What to Do After Miliary Tuberculosis?
After miliary tuberculosis, regular pulmonology and infectious disease follow-up is essential, with consultations scheduled at 1, 3, and 6 months after treatment completion, then annually. A control chest X-ray is performed at 6 months and 1 year to assess slow lesion resolution, which may sometimes leave scarring sequelae. Screening for functional sequelae is based on pulmonary function tests at 6 months, supplemented by chest CT scan if pulmonary fibrosis is suspected. Ophthalmologic monitoring with visual assessment is necessary at 1, 3, and 6 months for patients treated with ethambutol, while audiogram at the same intervals is required for those who received streptomycin or amikacin, with nephrology monitoring through creatinine and urine dipstick also recommended. Additionally, contact screening of close contacts with PPD or IGRA and chest X-ray should be organized, with isoniazid chemoprophylaxis for 6-9 months for infected individuals. Finally, each tuberculosis case must be notified to the national registry as part of the National Tuberculosis Control Program.
Why Choose Tunisia for Miliary Tuberculosis Management?
Tunisia has experienced pulmonologists, infectious disease specialists, and intensivists in tuberculosis management, with an active National Tuberculosis Control Program (PNLAT). Equipment is modern: chest CT scan, GeneXpert PCR (available in several university hospitals and private laboratories), bronchoscopy, mycobacterial culture laboratory (university hospitals), ventilatory ICUs, intracranial pressure monitoring (for meningitis).
Advantages
In Tunisia, diagnosis of miliary tuberculosis benefits from rapid execution thanks to the availability of GeneXpert PCR, obtainable in just 2 hours in university hospital centers such as La Rabta, Sahloul, or Fattouma Bourguiba, while mycobacterial culture results are obtained within 4-6 weeks. Anti-tuberculosis treatment is based on complete quadruple therapy combining isoniazid, rifampicin, pyrazinamide, and ethambutol, available in both oral and intravenous forms for severe cases, with dexamethasone corticosteroids systematically administered for associated tuberculous meningitis. A major advantage of the Tunisian health system is free care for tuberculosis patients in the public sector under the National Tuberculosis Control Program (PNLAT), while the private sector offers all-inclusive packages covering diagnostic tests and hospitalization. Finally, Tunisia offers simplified management for foreign patients, with streamlined formalities, direct coordination with international insurance companies, and multilingual reception in French, English, Arabic, and Italian.